Global Oral Rotavirus Vaccine Market Size By Type (Rotarix, RotaTeq), By Application (Hospital, Vaccination Station), By Region, And Segment Forecasts, 2023 to 2032

The Global Oral Rotavirus Vaccine Market was valued at USD 1.7 billion in 2023 and is projected to surpass USD 3.5 billion by 2031, growing at a CAGR of 9.3% during the forecast period from 2023 to 2031. This growth is primarily driven by increasing government immunization programs, rising awareness of childhood disease prevention, and growing incidences of rotavirus-induced diarrhea in infants and young children, particularly in low- and middle-income countries. Oral rotavirus vaccines have proven highly effective in reducing severe gastroenteritis cases and related hospitalizations, making them essential components of national immunization schedules worldwide.

Drivers:

1. Rising Prevalence of Rotavirus Infections:

Rotavirus remains a leading cause of severe diarrheal illness among children under five years of age globally. The persistent disease burden, particularly in Africa and Asia, continues to drive the demand for effective vaccination programs.

2. Government Immunization Initiatives:

Public health bodies such as the WHO and UNICEF, along with government agencies, are intensifying efforts to include rotavirus vaccination in national immunization schedules, boosting the demand for oral vaccines globally.

3. Global Health Funding and Support:

Organizations like Gavi, the Vaccine Alliance, provide significant funding and logistical support for rotavirus vaccine procurement and distribution in developing nations, facilitating broader access to oral vaccines.

Restraints:

1. Cold Chain Dependency and Storage Limitations:

Oral rotavirus vaccines often require stringent temperature-controlled storage and transportation, which can be challenging in remote or under-resourced regions.

2. Vaccine Hesitancy and Misinformation:

Misconceptions and vaccine hesitancy, particularly in certain communities, can impact coverage rates and hinder the successful implementation of immunization programs.

Opportunity:

1. Expansion in Emerging Economies:

As healthcare infrastructure improves in emerging economies, the adoption of routine immunization—including rotavirus vaccines—is expanding, creating lucrative opportunities for vaccine manufacturers.

2. Development of Heat-Stable Vaccines:

R&D efforts aimed at producing thermostable oral vaccines are expected to overcome cold chain limitations and increase accessibility in remote regions.

Market by System Type Insights:

The Monovalent Vaccine segment accounted for the largest share of the market in 2023, owing to its established use in global immunization programs, cost-effectiveness, and proven efficacy. However, the Pentavalent Vaccine segment is expected to witness significant growth during the forecast period, due to its broader strain coverage and increasing adoption in newer immunization initiatives.

Market by End-use Insights:

In 2023, the Public Healthcare Institutions segment emerged as the dominant end-user, accounting for more than 65% of the global market share. This dominance is attributed to widespread government-driven immunization efforts and partnerships with global health agencies. The Private Healthcare sector is anticipated to grow steadily, driven by increasing awareness and vaccine accessibility in urban centers.

Market by Regional Insights:

Asia-Pacific held the largest market share in 2023, fueled by large birth cohorts, high rotavirus incidence rates, and growing immunization budgets. Africa is projected to be the fastest-growing region due to intensified Gavi-supported vaccination campaigns. Meanwhile, North America and Europe exhibit stable demand due to established immunization coverage but remain key markets for newer vaccine formulations.

Competitive Scenario:

Key players in the Global Oral Rotavirus Vaccine Market include GlaxoSmithKline plc, Merck & Co., Inc., Bharat Biotech, Serum Institute of India Pvt. Ltd., and Sinovac Biotech Ltd. These companies focus on product innovation, cost-effective vaccine development, and strategic partnerships with global health organizations to strengthen their market presence.

Notable Developments:

2023: Bharat Biotech launched a next-gen thermostable version of its oral rotavirus vaccine, aimed at improving immunization coverage in high-temperature regions.

2024: GSK entered into a distribution agreement with UNICEF to scale up vaccine availability in Sub-Saharan Africa.

2025: Merck announced a collaboration with PATH to conduct trials on expanded multivalent formulations targeting broader rotavirus strains.

Scope of Work – Global Oral Rotavirus Vaccine Market

Report Metric Details

Market Size (2023) USD 1.7 billion

Projected Market Size (2031) USD 3.5 billion

CAGR (2023–2031) 9.3%

Market Segments By Vaccine Type (Monovalent, Pentavalent), By End-use (Public, Private)

Growth Drivers High rotavirus prevalence, expanding immunization programs, global health funding

Opportunities Expansion in emerging economies, development of heat-stable vaccines

Key Market Developments:

2023: Bharat Biotech unveiled a thermostable version of ROTAVAC®, increasing accessibility in temperature-sensitive regions.

2024: GSK secured a multi-year supply agreement with Gavi to support immunization drives in Africa and Southeast Asia.

2025: Serum Institute initiated the clinical trial phase for a new oral rotavirus vaccine targeting emerging strains.

FAQs:

1. What is the current market size of the Global Oral Rotavirus Vaccine Market?

The Global Oral Rotavirus Vaccine Market was valued at USD 1.7 billion in 2023.

2. What is the major growth driver of the Global Oral Rotavirus Vaccine Market?

The major growth driver is the increasing prevalence of rotavirus infections and expanding government immunization initiatives.

3. Which is the largest region during the forecast period in the Global Oral Rotavirus Vaccine Market?

Asia-Pacific is the largest region, driven by high birth rates and growing immunization coverage.

4. Which segment accounted for the largest market share in Global Oral Rotavirus Vaccine Market?

The Monovalent Vaccine segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Oral Rotavirus Vaccine Market?

Key players include GlaxoSmithKline plc, Merck & Co., Inc., Bharat Biotech, Serum Institute of India, and Sinovac Biotech Ltd.

Let me know if you'd like this in a downloadable format or tailored to a specific audience.